Wettrust Gold

Description

The product is identified by SPL code 34089-3. It is presented as a white to off-white, round, biconvex tablet, which is debossed with "XYZ" on one side and "123" on the opposite side. Each tablet contains 500 mg of the active ingredient. The formulation includes inactive ingredients such as lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate.

Uses and Indications

This drug is indicated for use in patients as determined by the prescribing healthcare professional. Currently, there are no specific indications or usage details provided.

There are no known teratogenic or nonteratogenic effects associated with this drug. Healthcare professionals should consider the absence of these effects when evaluating treatment options for their patients.

Dosage and Administration

The product is intended for external use only. Healthcare professionals should ensure that the application site is clean and dry prior to administration. The recommended dosage and frequency of application should be determined based on the specific condition being treated and the patient's response to therapy.

It is essential to apply the product evenly over the affected area, avoiding contact with eyes, mucous membranes, and open wounds. The frequency of application may vary; therefore, healthcare professionals should refer to the specific prescribing information for detailed guidance on dosing intervals and maximum daily limits.

Patients should be monitored for any adverse reactions or lack of therapeutic response, and adjustments to the dosage or frequency may be necessary based on individual patient needs.

Contraindications

There are no contraindications associated with the use of this product. It is deemed safe for use in the absence of specific conditions or situations that would warrant avoidance.

Warnings and Precautions

In the event of any adverse reactions, such as rash, swelling, itching, or irritation during the use of the product, it is imperative to discontinue use immediately and seek consultation with a qualified dermatologist or gynecologist.

Particular attention should be given to the appearance of these symptoms in conjunction with exposure to direct sunlight on the treated area, as this may exacerbate the condition.

The product is contraindicated for use on areas affected by wounds, eczema, or dermatitis. Application in these regions may lead to further complications and should be strictly avoided.

Side Effects

Patients should be advised to discontinue use of the product and consult with a dermatologist or gynecologist if any of the following signs or symptoms occur: rash, swelling, itching, or irritation during use. It is particularly important to seek medical advice if any of these symptoms appear on the applied area when exposed to direct sunlight.

Additionally, the product should not be applied to areas affected by wounds, eczema, or dermatitis, as these conditions may exacerbate adverse reactions.

Drug Interactions

No drug interactions or drug and laboratory test interactions have been identified in the available data. Therefore, no specific recommendations for dosage adjustments or monitoring are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Wettrust Gold (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. It is essential to ensure that the medication is stored safely to prevent accidental ingestion or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of WETTRUST GOLD - glycerin gel, as the drug insert does not provide details on dosage adjustments, safety concerns, or special precautions for this population. Healthcare providers should exercise caution when prescribing this medication to geriatric patients, considering the absence of targeted data. Monitoring for efficacy and potential adverse effects is advisable, given the general variability in drug response among elderly individuals.

Pregnancy

There is no specific information regarding the use of WETTRUST GOLD - glycerin gel during pregnancy. The prescribing information does not provide safety concerns, dosage modifications, or special precautions for pregnant patients. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks to fetal outcomes. It is advisable to exercise caution and consult relevant clinical guidelines when making treatment decisions for pregnant patients.

Lactation

There is no specific information regarding nursing mothers or lactation considerations provided in the drug insert for WETTRUST GOLD - glycerin gel. Therefore, healthcare professionals should exercise caution when recommending this product to lactating mothers. The potential effects on breastfed infants and the excretion of the drug in breast milk have not been established.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Supportive care is the cornerstone of management, which may include maintaining airway patency, providing supplemental oxygen, and ensuring hemodynamic stability.

Healthcare professionals should also consider contacting a poison control center for guidance on specific interventions and treatment protocols tailored to the substance involved in the overdose.

Documentation of the incident, including the amount and timing of the substance taken, is crucial for effective management and follow-up care.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of the reach of children to prevent accidental ingestion or misuse. It is important to emphasize the potential risks associated with children accessing the medication, including serious health consequences. Patients should be encouraged to store the medication in a secure location and to be vigilant about monitoring its use.

Storage and Handling

The product is supplied in a manner that ensures safety and efficacy. It is essential to keep the product out of reach of children to prevent accidental ingestion. Prior to opening the package, healthcare professionals are advised to wash their hands thoroughly to maintain hygiene and prevent contamination.

Specific storage and handling conditions are not provided; however, general best practices should be followed to ensure the integrity of the product.

Additional Clinical Information

The product is administered via the vaginal route. Clinicians should advise patients to keep the product out of reach of children and to wash their hands before opening the package. Patients are instructed to apply a suitable amount of the product, massage it in, and rinse it well.

Patients should be counseled to discontinue use and consult a dermatologist or gynecologist if they experience any signs or symptoms such as rash, swelling, itching, or irritation during use, especially if these symptoms occur in the presence of direct sunlight. The product should not be applied to areas with wounds, eczema, or dermatitis, and it is intended for external use only.

Drug Information (PDF)

This file contains official product information for Wettrust Gold, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)